Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.
2506 Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. MDX-1106, a fully human IgG4 PD-1 blocking antibody, has shown antitum...